Clinical trial sites anticipate disruption due to Covid-19; FDA issues guidance for trials amid pandemic
In a survey of 170 sites, Continuum Clinical found that around one-third of sites anticipate impacts on their ability to recruit and retain participants. The FDA guidance listed considerations patient protection and conduct of trials during the pandemic.